Integrium, LLC to Discuss Alternative Financing Solutions for Biotech during J.P. Morgan 36th Annual Healthcare Conference Week

By: Emily MacHale

Tustin, CA – Integrium, LLC Executives will be in San Francisco during the J.P. Morgan 36th Annual Healthcare Conference on January 8-11, 2018. Being in San Francisco during the conference over the past 7 years, Integrium is able to continue connecting with biotech, medical device, and diagnostic companies, while building new relationships and cross-pollinating a wide span of industry sectors.

The JPM Conference is expecting to host over 400 public and private companies, in addition to more than 8,000 guests. Being the largest healthcare investment conference in the industry, Integrium values the opportunity to connect with investors and like-minded folks looking to collaborate and develop strategic partnerships.

Integrium will be available for meetings January 8-11, 2018 and encourages guests to reach out to Emily MacHale, Associate Director of Marketing & Research at for any meeting requests.

About Integrium

Founded in 1998 by visionary clinical research thought leaders, Integrium is a full-service Phase I-IV clinical CRO that specializes in a wide range of therapeutic areas. Integrium plays a key role in furthering new medical advancements by helping pharmaceutical companies design and execute clinical studies, ensuring they achieve their objectives on time, on budget, and with expected quality.

Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the New Chemical Entity, 505(b)(2) and Generic space attain clinical data so they can raise the next round of capital. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule II drugs and Oncology.

Check out our new website!

To learn more about Integrium, contact:
Emily MacHale
Associate Director of Marketing & Research